deferoxamine

(redirected from Deferroxamine)

deferoxamine

 [de″fer-oks´ah-mēn]
an iron-chelating agent isolated from Streptomyces pilosus, used as an antidote in iron poisoning.

deferoxamine

Deferoxamine mesylate Hematology A trihydroxamic acid produced by Streptomyces pilosus that ↑ urinary iron excretion; it is the only FDA-approved iron-chelating agent for clinical use; early use of deferoxamine in thalassemia major ↓ transfusion-related iron overload and protects against DM, cardiac disease, early death. See Hemochromatosis.

deferoxamine

A chelating agent used to treat iron compound poisoning. The drug is on the WHO official list.
References in periodicals archive ?
Conjugation of LEM2/15 to desferrioxamine was achieved via an N-succinimidyl linkage in an mAb: deferroxamine ratio of approximately 1 : 2-3 as reported previously [19].
Effects of deferroxamine, ferroxamine and iron on experimental mucormycosis.
Iron is essential for the virulence and growth of Mucorales so the conditions associated with iron overload like hematologic malignancies or hemodialysis with deferroxamine therapy can be predisposing factors for the infection (19).
KEY WORDS: Deferroxamine, Deferiprone, Deferasirox, Combination, Sequential, Thalassemia Major.
This study demonstrated that both combinations of Deferroxamine/Deferiprone (Com DFO/DEF) and alternating sequential of Deferasirox (Osveral)/ Deferroxamine (Seq OSV/DFO) have a similar significant effect in decreasing of serum ferritin.Com DFO/DEF is a familiar regimen to most clinicians, but SeqOSV/DFO is the first trial which applied in TM patient to date.
Out of 61 patients thirty were treated by deferroxamine (DFO) and 31 were on the combination of DFO and deferiprone (DEF) protocol therapy.